Why Hong Kong, Asia?
Hong Kong is the undisputed capital of MedTech investment and innovation in Asia. In 2025, the city ranked #1 globally for biotech IPOs, with HKEX-listed firms raising $17.5 billion since 2018. With 1,500+ VC funds managing over $200 billion in assets and a combined healthcare market cap of HK$4.8 trillion, the financial case speaks for itself.
Beyond capital, Hong Kong sits at the gateway of the Greater Bay Area, a $2 trillion, 86-million-person corridor spanning Hong Kong, Shenzhen, and Guangzhou, covering every stage of the MedTech value chain. It is the only city that combines international legal protections with direct access to mainland China’s market, a functioning regulatory bridge to the NMPA, and rapid prototype-to-production capabilities that no other city in Asia can match.
It is in this city that MedTech World Asia | Hong Kong 2026 will take place, hosted at the HKCEC on 26 to 28 August, uniting regulators, hospital executives, investors, corporates, and innovators defining
